Form 8-K - Current report:
SEC Accession No. 0001193125-23-156713
Filing Date
2023-05-30
Accepted
2023-05-30 17:16:32
Documents
13
Period of Report
2023-05-25
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d487635d8k.htm   iXBRL 8-K 38397
2 EX-3.1 d487635dex31.htm EX-3.1 6133
  Complete submission text file 0001193125-23-156713.txt   178336

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA phat-20230525.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE phat-20230525_lab.xml EX-101.LAB 19482
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE phat-20230525_pre.xml EX-101.PRE 12165
7 EXTRACTED XBRL INSTANCE DOCUMENT d487635d8k_htm.xml XML 3683
Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Filer) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39094 | Film No.: 23977729
SIC: 2834 Pharmaceutical Preparations